BP
ZBH icon

Ballentine Partners’s Zimmer Biomet ZBH Stock Holding History

Ballentine Partners’s Portfolio ZBH Stock Details ZBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350K Buy
4,070
+560
+16% +$49.1K ﹤0.01% 714
2026
Q1 		$317K Buy
3,510
+162
+5% +$14.9K ﹤0.01% 711
2025
Q4 		$301K Sell
3,348
-51
-2% -$4.84K ﹤0.01% 721
2025
Q3 		$335K Sell
3,399
-249
-7% -$24.7K ﹤0.01% 668
2025
Q2 		$333K Sell
3,648
-140
-4% -$13.5K 0.01% 651
2025
Q1 		$429K Sell
3,788
-783
-17% -$83.8K 0.01% 494
2024
Q4 		$483K Buy
4,571
+716
+19% +$76.8K 0.01% 434
2024
Q3 		$416K Buy
3,855
+73
+2% +$7.97K 0.01% 473
2024
Q2 		$410K Sell
3,782
-175
-4% -$20.6K 0.01% 451
2024
Q1 		$522K Buy
3,957
+100
+3% +$12.5K 0.01% 378
2023
Q4 		$469K Buy
3,857
+41
+1% +$4.58K 0.01% 383
2023
Q3 		$428K Sell
3,816
-3
-0.1% -$381 0.01% 347
2023
Q2 		$556K Sell
3,819
-320
-8% -$43.5K 0.01% 291
2023
Q1 		$535K Buy
4,139
+7
+0.2% +$879 0.01% 288
2022
Q4 		$527K Buy
4,132
+2
+0% +$232 0.02% 269
2022
Q3 		$432K Buy
4,130
+217
+6% +$23.8K 0.01% 270
2022
Q2 		$412K Sell
3,913
-103
-3% -$12.2K 0.01% 264
2022
Q1 		$513K Buy
4,016
+221
+6% +$26.6K 0.02% 253
2021
Q4 		$468K Buy
3,795
+58
+2% +$7.59K 0.01% 282
2021
Q3 		$531K Buy
3,737
+4
+0.1% +$588 0.02% 228
2021
Q2 		$583K Buy
3,733
+1,215
+48% +$197K 0.02% 214
2021
Q1 		$391K Sell
2,518
-60
-2% -$9.29K 0.01% 260
2020
Q4 		$386K Hold
2,578
– – 0.02% 244
2020
Q3 		$340K Buy
2,578
+4
+0.2% +$523 0.02% 271
2020
Q2 		$299K Buy
2,574
+28
+1% +$3.23K 0.01% 278
2020
Q1 		$251K Sell
2,546
-156
-6% -$20.4K 0.01% 280
2019
Q4 		$393K Buy
2,702
+34
+1% +$4.69K 0.02% 252
2019
Q3 		$355K Buy
2,668
+232
+10% +$30K 0.02% 258
2019
Q2 		$278K Buy
2,436
+202
+9% +$23.7K 0.01% 305
2019
Q1 		$277K Sell
2,234
-17
-0.8% -$1.93K 0.01% 256
2018
Q4 		$227K Buy
+2,251
New +$253K 0.01% 284

Other funds holding ZBH

DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
WAM
Wilsey Asset Management San Diego, California $681M AUM 6.7% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return
QAM
QSM Asset Management London, United Kingdom $193M AUM 47.49% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
NCM
Northside Capital Management Hood River, Oregon $1.22B AUM 20.77% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
GHAM
Gilman Hill Asset Management New Canaan, Connecticut $731M AUM 19.41% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Ballentine Partners's ZBH Position: Q2 2026 in Review

Ballentine Partners increased its Zimmer Biomet (ZBH) stake by 16% in Q2 2026, buying an estimated $49.1K and bringing the position to 4,070 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #714.

Ballentine Partners first reported a position in ZBH in Q4 2018 and has held it in 31 quarters since. The position peaked at $583K in Q2 2021. 141 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.

  • Ballentine Partners held 4,070 shares of Zimmer Biomet worth $350K as of Q2 2026.
  • Ballentine Partners bought 560 Zimmer Biomet shares in Q2 2026, an estimated $49.1K.
  • Zimmer Biomet made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #714 holding.
  • Ballentine Partners first reported a position in Zimmer Biomet in Q4 2018 and has held it in 31 quarters since.
  • Ballentine Partners's Zimmer Biomet position peaked at $583K in Q2 2021.
  • 141 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.